On a 12‑week, randomized, double‑masked, placebo‑controlled Phase 2a study of urcosimod for neuropathic corneal pain (NCP), 12 participants were enrolled, with six receiving 0.05 % urcosimod and six receiving placebo. Patients treated with urcosimod reported a mean 4.5‑point increase in their ability to enjoy life and relationships, a 1.5‑point improvement in mood, and a 3.0‑point decline in time spent thinking about eye pain, compared with no change, 0.5‑point improvement, and 1.5‑point decline in the placebo group, respectively. These quality‑of‑life gains build on earlier pain‑reduction data from the same trial and suggest that urcosimod may offer broader therapeutic benefits beyond pain relief.
Neuropathic corneal pain has no FDA‑approved treatments, making urcosimod’s positive outcomes particularly noteworthy. The drug has Fast Track designation from the FDA, and OKYO Pharma plans to present the full dataset at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) scheduled for May 3‑7, 2026. The company also intends to advance urcosimod into larger confirmatory studies, including a multi‑center Phase 2b/3 trial, to support regulatory approval.
Management and scientific commentary underscore the significance of the findings. Principal investigator Pedram Hamrah, MD, stated, "the data 'suggests that urcosimod may not only reduce pain but also support the restoration of corneal nerve architecture'— a critical step toward establishing additional mechanistic insights." OKYO Pharma is a clinical‑stage biopharmaceutical company with no revenue and a net loss of $4.71 million in Q2 2026 and $4.6 million for the trailing 12 months ending September 30 2025. Its market capitalization is approximately $84 million, with shares trading near $1.60. The company recently completed a public offering of ordinary shares expected to raise about $20 million in gross proceeds, bolstering its cash runway for ongoing development.
The quality‑of‑life data strengthens urcosimod’s development pipeline and may enhance investor confidence, but the company remains focused on research and development with significant cash burn. The results support the potential for regulatory approval and underscore the unmet medical need in NCP, positioning urcosimod as a promising candidate in a market with no approved therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.